Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 31, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : RQ3013
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Walvax Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Fudan University
Deal Size : Undisclosed
Deal Type : Collaboration
Towards an effective mRNA vaccine against 2019-nCoV
Details : A joint research team from Fudan University, Shanghai JiaoTong University, and RNACure Biopharma is currently working on a vaccine for COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 03, 2020
Lead Product(s) : mRNA Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Fudan University
Deal Size : Undisclosed
Deal Type : Collaboration